

Scientific Program as at 2 November 2017

Subject to change

Tuesday 5 December 2017

09:00 - 18:00	Registration desk open				
10:00 start	ASCEPT Board meeting (10:00 - 12:30)	Workshop: Careers and Early Stage Biomedical Translation (10:00 – 16:45)	Pharmacogenomics Workshop (10:00 – 12:00)	Council of Pharmacy Schools meeting (10:00 – 12:30)	
		Supported by	Chair: Prof Andrew Somogyi		
		Accelerating Australia Supported by MTPConnect Meditech and Pharma Growth Centre	Thiopurine pharmacogenetics: From classic simplicity to modern complexity Dr John Duley, The University of Queensland		
		10:00 – 12:30 Overview of the Life Sciences Industry from an Australian Perspective - Transformational stage of the industry resulting in opportunities for biomedical entrepreneurs	Research and education programs facilitating evidence- based clinical implementation of pharmacogenomics and precision medicine in Australia Assoc Prof Liz Milward, The University of Newcastle		
		What is a biomedical entrepreneur? Prof Maree Smith, The University of Queensland and	Student/ECR short presentations Pharmacogenomics SIG AGM		
		Prof Darren Kelly, The University of Melbourne	Education Forum (12:30 – 16:30)	Clinical Pharmacology Workshop (14:30 – 17:00)	
		12:30 – 13:15 Lunch	ASCEPT Education Forum AGM	Clin Pharm Noir — A case- based, interactive workshop	
		13:15 – 16:45 What is happening in our biomedical translation ecosystem? - Facilitated and	Engaging students in the digital world Dr Kirsten Staff and Dr Sheridan Gentili	on forensic toxicology Can the living help the deceased?	
		interactive workshop to identify the main hurdles for biomedical translation in Australia from the perspective of participants	Preparing educators to deal with the challenges of an ever-changing higher education environment	Assoc Prof Darren Roberts, NSW Poisons Information Centre, Sydney Children's Hospital Network, Westmead	
			Assoc Prof Lesley Lluka, The University of Queensland and Assoc Prof Shane Bullock, Monash University	The final consult Prof Nick Buckley, The University of Sydney	
				Poisoning through the ages Prof Ian Whyte, Calvary Mater Newcastle	
17:00 – 18:00	Conference opening and Japanese Pharmacological Society keynote address				
	Prof Yuichi Sugiyama, Sugiyama Laboratory, RIKEN Innovation Center, Japan				
18:00 – 19:30	Welcome reception Boulevard Auditorium Foyer,	Brisbane Convention and Exhibition Co	entre		

Wednesday 6 December 2017

07:30 - 18:00	Registration desk open					
08:30 - 09:30	APSA lecture	APSA lecture				
	Reflections and connections on a pharmacokinetic journey					
	Prof Kevin Batty, School of Pharmacy, Curtin University					
09:30 – 10:20	Morning tea with exhibitors	cular Clinical Pharmacology Dr.	ua Discovery Toyicology	ADSA Council Mosting		
	Pharmaceutical Science	cular, Clinical Pharmacology, Dru	ig Discovery, Toxicology,	APSA – Council Meeting		
10:25 – 12:30	Symposium 1: Cannabinoids	Symposium 2: Mice, modelling	Symposium 3: Optimising	Symposium 4: Novel aspects of		
	for patients: Getting the	and post-marketing	teaching to enhance student	drug metabolising enzymes -		
	pharmacology right first time	surveillance to inform medication efficacy and safety	outcomes	structure, function and regulation		
	Supported by	Thedication emcacy and safety		regulation		
	Quoonsland					
	Queensland Government					
	Chair: Prof Jennifer Martin	Chaire: Dr Daniiola Gniidic and	Chairs: Dr Lynette Fernandes	Chairs: Prof Ross McKinnon and		
	Cidir. Pror Jenniner Martin	Chairs: Dr Danijela Gnjidic and Assoc Prof Simon Bell	and Dr Greg Maynard	Prof Peter Mackenzie		
10:25 – 10:50	Understanding cannabinoid	Preclinical models to	Introducing a large-scale	Cytochrome P450 structure -		
	clinical pharmacology in order	understand the risks of single	research project for	function: Insights from		
	to drive clinical studies	and multiple concurrent	undergraduate students	molecular dynamics		
	Dr Catherine Lucas, University of Newcastle	medicines in old age Dr John Mach, Kolling Institute	Assoc Prof Susan Rowland, The University of Queensland	simulations Prof John Miners and Dr		
		of Medical Research; The	The entre stay of Queensiana	Pramod Nair, Flinders University		
		University of Sydney				
10:50 – 11:15	Cannabinoids for patients:	Application of pharmacometric	Peer assessment to develop	CYP2J2 over-expression in		
	Comparative efficacy and toxicity in paediatric setting	modelling for studying drug effects	critical analysis and self- reflection in large	breast cancer cells drives tumourigenesis and anti-cancer		
	Prof Noel Cranswick,	Prof Carl Kirkpatrick, Monash	undergraduate cohorts	drug resistance		
	Melbourne University	University	Dr Rosa McCarty, The	Prof Michael Murray, The		
			University of Melbourne	University of Sydney		
11:15 – 11:40	High quality human cannabinoid analytics to drive	Novel approaches in pharmacoepidemiological	The development of interprofessional	New insights into UDP- glucuronosyltransferase		
	clinical studies	studies to communicate	communication skills for	regulation and function in		
	Dr Peter Galettis, University of	benefits and risk of medicines	collaborative practice	cancer		
	Newcastle	Dr Danijela Gnjidic, The	Dr Karen Luetsch, The	Dr Robyn Meech, Flinders		
11:40 – 12:05	Pharmacokinetic analysis of	University of Sydney Pharmacoepidemiological	University of Queensland Student perspectives on peer	University Arylamine N-acetyltransferase-		
11.40 12.03	vaporized cannabinoids	studies to inform medication	assessment, feedback and	1: Drug metabolism and more		
	through inhalation	safety in older adults with	team work	Dr Neville Butcher, The		
	Dr Zheng Liu, The University of	chronic diseases and dementia	Jayden Kelly and	University of Queensland		
	Melbourne	Assoc Prof Simon Bell, Monash University	Mohammdali (Ali) Taher, Monash University			
12:05 – 12:30	Pharmaceutical Aspects of	Changing guideline	Panel discussion	Sulfotransferase: Structure,		
	Cannabis	recommendations on the		function and protein-protein		
	Assoc Prof Jennifer Schneider,	pharmacological management		interactions		
	University of Newcastle	of back pain Assoc Prof Christine Lin, The		Prof Rodney Minchin, The University of Queensland		
		George Institute for Global				
		Health				
12:30 – 13:25	Lunch with exhibitors Poster presentations: Cardiovas	cular Clinical Pharmacology	APSA AGM with lunch (12:30 -	-14:00)		
	Drug Discovery, Toxicology, Ph		Ar SA AGIVI WILITIUIILII (12.30 -	1 1.00)		
13:30 - 15:30	Oral presentations 1:	Oral presentations 2:				
	Cardiovascular	Drug Discovery/				
13:30 – 13:45	Cardiomyocyte ErbB4	Pharmaceutical Science Quantification of metformin in				
13.30 - 13.43	receptors are essential for	human serum by hydrophilic				
	cardiac hypertrophy and	interaction liquid				
	growth of neonatal mice, and	chromatography - mass				
	contribute to maintenance of	spectrometry				
	cardiac function in adult hearts.	Dr Ahmed Abdalla, University of South Australia				
	Dr Melissa Reichelt, The	or south Australia				
		1				

Comparing the anti-filtrotic effects of emerging treatments: Serelation and during mammany gland involution in the first principle of the property of Cucendand involution in the property of Cucendand involution of the property of the prop					
treatments: Serelavin and the Rap Prinhibitor, PH-418 to a clinically used angiotensia receptor blocker and ACE inhibitor in a high salt-induced mouse model of kidney disease. It was considered to the process of the	13:45 – 14:00				
IRAP inhibitor, HH-H35 to a clinically-used anglostensin receptor blocker and ACE inhibition in a high salt-induced mouse model of kidney disease. Mr Matthew Shen, Monash Linwersity Procedinated pharmacokinetic delegation of rate mesenteric arteries Dr Sranh Wright, University of New South Wales Part and the state of the sta		effects of emerging	death during mammary gland		
clinically-used anglotensian receptor blocker and ACE inhibitor in a high salt-induced mouse model of kidning disease. Contempt of the physiosian researcher carriers or Farman School (TRPC3) in endothelium-dependent vasodilation of ratio (See 1978) and (See		treatments: Serelaxin and the	involution		
dilinically-used anglotensian receptor blocker and A.C. Inhibitor in a high salt-induced mouse model of kidning disease. 14:00 – 14:15 Robert PRPC3 in endothelium-dependent vasodilation of rational pharmacokinetic dependent vasodilation of rational pharmacokinetic dependent vasodilation of rational pharmacokinetic dependent vasodilation of rational pharmacokinetics of prison of the hypodia-material pharmacokinetics of prison pharmacokinetics of pr		IRAP inhibitor, HFI-419 to a	Dr Felicity Davis, The University		
receptor blocker and A.C. inhibitor in a high sair-induced mouse model of kidney disease. Mr Matthew Shen, Monash University of New Form of Police of TPC3 in endothelium activated cytorionis NS36505 p. New South Wales 14:10 – 14:15 Role of TPC3 in endothelium development of the hypoxid-activation of ratimesenteric arteries on New South Wales 14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abonimal arort can enuryms Mr Kali Fan, Monash University of Deriversity of Capenhagen, Denmark 14:30 – 14:45 Inhibition of the transient receptor potential melistatin receptor potential melistatin receptor potential melistating improves cardiac function in a revive model of sichaemia/reperfusion injury University of Sichaemia/reperfusion injury University of Gueensland University of Gueensland University of Technology 14:45 – 15:00 Defining the progression of diabetic cardiomyopathu in amouse model of type 1 diabetes Defining the progression of diabetes are progression of diabetes and cardiac-selective targeting of histore advanced by Particular and California and Capetal Cape		clinically-used angiotensin	-		
inhibition in a high salt-induced misease. Mr. Matthew Shen, Monash University of Linkersity of Link					
mouse model of kidney disease. Mr Matthew Shen, Monash University of Landschellum-dependent vascodilation of rat mesenteric arteries of Po Sarah Wright, University of Po New South Wales 14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abproach for investigating of Copenhagen, Demmark Mr Kaki Fan, Monash University of Sydney Mr Matthew Bull, Mr Matthew Bull, Mr Matthew		•			
disease. Mr Matthew Shen, Monash University 14:00 – 14:15 Role of TRPCI in endothellum-dependent vasodilation of rat mesenteric arteries Dr Sarah Wright, University of New South Wales Dr Sarah Wright, University of New South Wales A new high-throughput preatment to stabilise existing abdominal aortic aneurysms Mr Kaki Fan, Monash University 14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneurysms Mr Kaki Fan, Monash University 14:15 – 14:30 Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase University of Sophery Dr Tamara Paravicin, RMT7 Drimensity Dr Tamara Paravicin, RMT7 Drimensity		_			
Mr Matthew Shen, Monash University of London Fred Compensation of the State receptors by the 22-adrenergic and Mz muscarinic activity of Cueersland (University of Auckland, New 2ard and university of Fixed Park (Institute of States) (Park (Institute of					
University An every life in the transient receptor potential melastating / (T/RFM7) channel-kinase in an every known model of fisher haste energing and fix function in an ex-vivo model of fisher energing and fix many potential melastating / (T/RFM7) channel-kinase in an ex-vivo model of fisher energing and fix man ex-vivo model of fisher energing and fix man ex-vivo model of fisher energing for fix mater formal man for its activity of Queersland University of Queersland Category (Proposition on diabetic cardiomyopathu in a mouse model of type 1 diabetes and positions of diabetic ardioding and positions of diabetic ardioding to endogenous and positions of diabetes and cardiac-selective grace for monators and positions of carboplatin, etoposide and methiphalan (CEM) in children with individual and position in very long for firm and position in very long for firm and position of the transient receptor optential melastating / (T/RFM7) channel-kinase of the position of the transient and position of the transient of the position of the position of the position of the position of the transient of the position					
14:00 - 14:15 Role of TRPC3 in endothelium development of two devolopment of the hypoxia-development of the hypoxia-devolopment of hypoxia-devolopment of the hypoxia-devolopment of the hypoxia-devolopment of the hypoxia-devolopment of the hypoxia-devolopment of hypoxia-devolopment of the hypoxia-devolopment of hypoxia-devo		· ·			
dependent vasodilation of rat mesenteric arteries Dr Sarah Wright, University of New South Wales 14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneuryms Mr Kaki Fan, Monash University 14:30 – 14:45 Inhibition of the transient receptor potential melastation in an ex-vivo model of ischaemial/reperfusion in july Dr Tamara Parakini, RMIT University Tuniversity 14:45 – 15:00 Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneuryms Mr Kaki Fan, Monash University Treeph openhagen, Denmark CSKSSDYQC peptide conjugated N-trimethyl chipsensily programs a parakini, RMIT university of Sydney Time potential melastation in real time are vivo model of ischaemia/reperfusion in july Dr Tamara Parakini, RMIT university of Sydney 14:45 – 15:00 Tender Irangel Ira		· · · · · · · · · · · · · · · · · · ·			
mesenteric arteries Dr Sarah Wright, University of New South Wales Dr Sarah Wright, University of New South Wales Dr Sarah Wright, University of New South Wales Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneurysms Mr Kaki Fan, Monash University University A new high-throughput approach for investigating Dr Simon Foster, University of Copenhagen, Denmark Copenhagen, Denmark	14:00 – 14:15				•
Dr. Sarah Wright, University of New South Wales Dr. Sarah Wright, University of New South Wales A new high-throughput approach for investigating abdominal acritz naeuryms Mr. Kaki Fan, Monash University Dr. Simon Foster, University of Copenhagen, Denmark Dr. Simon Foster, University of Sydney Dr. Simon Foster, University of Sydney Dr. TiRPPAPI Channel-kinase improves cardiac function in an ex-vivo model of ischaemia/reperfusion injury Dr. Simon Foster, University of Sydney Dr. Tamara Paranidin, RMIT University Dr. Maria Equation of bitter taste receptors Wr. Flaid Ziao, The University of Gueensland Dr. Parania Paranidin, RMIT University Dr. Narral Islam, Queensland University of Technology Dr. Narral Islam, Queensland University of Technology Dr. Narral Islam, Queensland Dr. Elizabeth, Inhistone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr. Andrew Willis, Monash University Dr. Willes De Blasio, Baker Heart Elizabetic and Cardiac-selective trageting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr. Andrew Willis, Monash University Dr. Systemic and cardiac-selective trades for greeptor modulator, calhex2ia, unmasks novel mode-awtiching mechanism Dr. Karen Gregory, Monash University Dr. Systemic and cardiac-selective trades for greeptor modulator, calhex2ia, unmasks novel mode-awtiching mechanism Dr. Karen Gregory, Monash University of Sydney Dr. Systemic and cardiac-selective trades for greeptor modulator, calhex2ia, unmasks novel mode-awt					
New South Wales University of Auckland, New Zealand Pagin in Australia? Mrs Samanta Lalic, Monash University Anew high-thick neuroblastom and practical experiment to stabilise existing abdominal aortic aneurysms of PCR Internalisation in real-time progression of Mr Kaki Fan, Monash University Dr Simon Foster, University of Copenhagen, Denmark Dr Simon Foster, University of Sydney Dr Simon Foster, University of Copenhagen, Denmark Dr Simon Foster, University of Sydney Dr Simon Foster, University of Copenhagen, Denmark Dr Simon Foster, University of Sydney Dr Maramara Paravicini, RMIT Dr Simon Foster, University of Sydney Dr Simon			•	•	
2ealand Anew high-throughput treatment to stabilise existing abdominal aortic aneuryms Mr Kaki Fan, Monash University of Copenhagen, Denmark Health professionals' and epsoxide improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University of Gueensland Culversity of Easter Copton of Copenhagen Another		Dr Sarah Wright, University of	Dr Matthew Bull, The	persistent prescription opioid	of carboplatin, etoposide and
14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneurysms Mr Kaki Fan, Monash University of Dr. Simon Foster, University of Copenhagen, Denmark Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex-vivo model of ischaemia/reperfusion injury Dr. Tamara Paravidin, RMIT University Inversity 14:45 – 15:00 Functional regulation of bitter taste receptors by beta2-adrenegic and MZ muscarinic acetylcholine receptors by Cupensland Inversity Dr. Willes De Blasio, Baker Heart & Dieberts institute Defining the progression of diabetic cardiomyopathu in amouse model of type 1 diabetes and beta flabetes institute 15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (IADAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University Dr. Karen Gregory, Monash University Dr. Warrullis, Monash University Dr. Wa		New South Wales	University of Auckland, New	analgesic use for non-cancer	melphalan (CEM) in children
14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abdominal a ordic aneurysms of PCR Internalisation in real-time Dr Simon Foster, University of Copenhagen, Denmark 14:30 – 14:45 Inhibition of the transient receptor potential melastating / (TRMT) channel-kinase improves cardiac function in an ex vivo model of ischaemia/repertusion injury Dr Tamara Paraydini, RMT University 14:45 – 15:00 Tamara Paraydini, RMT University of Queensland University CSKSSDVQC peptide conjugated N-trimethyl chitosan enhance the oral bias valiability of gemidabine by targeting gobiet cells Assoc Prof Inigyuan Wen, University of Sydney 14:45 – 15:00 Temara Paraydini, RMT University of Queensland University 14:45 – 15:00 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes and Balsaio, Baker Heart & Diabetes institute 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes and Balsaio, Baker Heart & Diabetes institute 15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University of Sydney Mr Andrew Willis, Monash University of South Australia Driversity of Sydney Anew Individual paproach for investigating approach for investigating of Prevalence of potentially and paproach for investigating approach for investigating approach for investigating of Prevalence of potentially and paproach for investigating of Prevalence of potentially and provided provided and papers of the progression of diabetic cardiomyopathy Mr Andrew Willis, Monash University of Sydney Another Driversity of Sydney Dr Karen Gregory, Monash University of Sydney Another Driversity of Sydney The novel fatty acid epoxide analogue CTU targets the analogue CTU targets the analogue CTU targets the cardioliphic provided papers of provided papers of potentially professionals on medication use in breasteding; Comparative call analysis of t			Zealand	pain in Australia?	with high-risk neuroblastoma
14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneurysms Mr Kaki Fan, Monash University of Copenhagen, Denmark Properties of Copenhagen, Denmark University of Sydney University of Copenhagen, Denmark University of Sydney University of Copenhagen, Denmark University of Sydney University of Queensland University of Queensland University of Sydney				Mrs Samanta Lalic, Monash	Dr Janna Duong, The University
14:15 – 14:30 Targeting IRAP: A novel treatment to stabilise existing abdominal acritic aneurysms of PCR internalisation in real time Dr Simon Foster, University of Copenhagen, Denmark 14:30 – 14:45 Inhibition of the transient receptor potential melastatin / T(RPM7) channel-kinase improves cardiacia function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravichii, RMIT 14:45 – 15:00 Punctional regulation of bitter taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Monitoring NanoBRET ligand binding to endogenous adenosine AZB receptors Dr Elizabeth Dinstone, Harry Perkins Institute of Medical Research Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University of University of Sydney Amouse harder crough, The University of Sydney and the mitochondrion and depletes cardiomyopathy and the mitochondrion and tepletes the mitochondrion and depletes cardiomyopathy and the mitochondrion and tepletes and the mitochondrion and				University	
treatment to stabilise existing abdominal aortic aneurysms Mr Kaki Fan, Monash University of Maki Fan, Monash University of Copenhagen, Denmark 14:30 – 14:45 Inhibition of the transient receptor potential melastatin / T(RPM7) fannel-klinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University of Sudney, Dr Tamara Paravicini, RMIT University of Auckland, New Zealand 14:45 – 15:00 Functional regulation of bitter taste receptors by beta2-adrenergic and M2 muscardini acetylcholine receptors Mr Jilla Zhao, The University of Technology Mr Jilla Zhao, The University of Gueensland University of Technology 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes institute Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Rills Illustrated Research Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Rills Illustrated Research Monitoring NanoBRET ligand with the first institute of Medical Research Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Rills in Stitute of Medical Research Nor Markader Clough, The University of auckland, New Zealand Cultiversity of Auckland, New Zealand Queensland Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Rills Illustrated Research Monitoring NanoBRET ligand without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Triesprenoid metaltim analysis of Sydney and Australian propulation of the transient of the Cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University of Sydney	14:15 – 14:30	Targeting IRAP: A novel	A new high-throughput	· · · · · · · · · · · · · · · · · · ·	
abdominal acritic aneurysms Mr Kaki Fan, Monash University University Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex-vivo model of ischaemia/prepurtsion injury Dr Tamara Paravichir, RMIT Inversity of Auckland, New Zealand 14:45 — 15:00 Eunctional regulation of bitter taste receptors by beta2- adrenergic and MZ muscarinic acetylcholine receptors Mr Jillai Zhao, The University of Zealand University of Technology Dr Miles De Blasio, Baker Heart & Diabetes institute 15:15 — 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Mr Andrew Will	2.1.25			1 · · · · · · · · · · · · · · · · · · ·	
Mr Kaki Fan, Monash University Inhibition of the transient receptor potential melastatin 7 (TRPM7) Jananel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University Functional regulation of bitter taste receptors by beta2- adrenergic and M2 muscarinic acetylcholine receptors Mr Jillai Zhao, The University of Auckland, New Zealand University of Technology Molarity in an allow of the transient receptor potential melastatin 7 (TRPM7) Jananel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University Mr Jillai Zhao, The University of Auckland, New Zealand University of Auckland, New Zealand University of Technology Molitoring NanoBRET ligand inding to endogenous adenosine A2B receptors Dr Miles De Blasio, Baker Heart & Diabetes institute Monitoring NanoBRET ligand inding to endogenous adenosine A2B receptors Dr Miles De Blasio, Baker Heart & Diabetes institute Monitoring NanoBRET ligand inding to endogenous adenosine A2B receptors Dr Miles De Blasio, Baker Heart & Diabetes institute Monitoring NanoBRET ligand inding to endogenous adenosine A2B receptors Dr Miles De Blasio, Baker Heart & Diabetes institute Monitoring NanoBRET ligand inding to endogenous adenosine A2B receptors Mr Mitchell Redston, The University of Sydney Mr Mitchell Redston, The University of Sydney Triterpenoid micellar anoparticles for the treatment of glioblastoma: Potential inhibition of the transient receits professionals on medication use in breastfeeding: Comparative call analysis of two national medicines call centres Dr Tireasure McGuire, The University of Olgensiand University of Muckland, New Zealand The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Mitchell Redston, The University of Sydney Triterpenoid micellar anoparticles for the treatment of glioblastoma: Potential inhibition of the Pl3K/Akt signaling Dr Rebecca Roubin, The University of Sydney				•	
University Dr. Simon Foster, University of Copenhagen, Denmark Dr. Simon Foster, University of Copenhagen, Denmark University of Sydney Id-30 – 14:45 Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr. Tamara Paravicini, RMIT University of Junersity of Queensland Id-45 – 15:00 Id-45 – 15:00 Id-46 – 15:00 Id-46 – 15:15 Defining the progression of diabetic cardiomyopathu in amouse model of type 1 diabetes Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute Dr. Miles De Blasio, Baker Heart & Diabetes Institute of Medical Research Dr. Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr. Karen Gregory, Monash University of Sudney Dr. Karen Gregory, Monash University of Sudney Mr. Antitrombotic prescribing for patients with a history of atrial fibrillation: An analysis of the University of Sydney Mr. Altitrombotic prescribing for patients with a history of atrial fibrillation and predicted use in public and health professionals on medication use in breastreeding: Comparative call analysis of two national medications are independent on the professional son medication use in lower interest and predicted in vivo exposure of i		•		_	
Copenhagen, Denmark University of Sydney Cells College C		,			
14:30 – 14:45 Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex-vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University 14:45 – 15:00 14:45 – 15:00 Functional regulation of bitter taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in mouse model of type 1 diabetes Dr Monitoring NanoBRET ligand binding to endogenous adnosine A2B receptors Dr Elizabeth Johnstone, Harry Prekins institute Monitoring NanoBRET ligand binding to endogenous adnosine A2B receptors or Caleactylase 4 (HDACa) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Systemic and cardiac-selective targeting of histone (elacetylase 4 (HDACa) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Techtor of patients with a history of atrial fibrillation: An analysis of the progression of diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Niles De Blasio, Baker Heart & Robert George (HDACa) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Niles De Gregory, Monash University The potential of MK2 inhibitors or atrial history of atrial fibrillation: An analysis of the diction and health professionals on medication us in breast feeding: Comparative call analysis of two national medicines of		Oniversity	-	_	
14:30 - 14:45 Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University of Auckland, New Zealand Nicotine-loaded chitosan anoparticulate dry powder inhaler formulation for its activity of Queensland Nicotine-loaded chitosan anoparticulate dry powder inhaler formulation for its activity of Queensland No Filiazabeta Indiates No Filiazabeta Indiata Indiates No Filiazabeta Indiates No Filiazabeta Indiates			Copennagen, Denmark	University of Sydney	
14:30 – 14:45 Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University of Mr Jilai Zhao, The University of Queensland 14:45 – 15:00 Interest of Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes institute Interest of Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes and labetes archy Dr Miles De Blasio, Baker Heart & Dr Miles Queensland University of Mr Jilai Zhao, The University of Queensland Interest of Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes archy Dr Miles De Blasio, Baker Heart & Diabetes institute Interest of Defining the progression of diabetec ardiomyopathy Mr Andrew Willis, Monash University Interest of Medical Research Induction of Amalysis tailing for patients with a history of ing floblastoma therapy of practical flowing for patients with a history of Sydney Interest of Fire Medical Research Research Induction of Amalysis using Medicinelnsight data Dr Daniel Taylor, NPS Medicinelnsight data Dr Daniel					,
receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University Dr Tamara Paravicini, RMIT University of Auckland, New Zealand 14:45 – 15:00					
T(TRPM7) channel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University of Auckland, New Zealand Dioavailability of geniciability of participation of bitter taste receptors by beta-adrenergic and MZ muscarinic acetylcholine receptors Mr. Jilai Zhao, The University of Queensland Dioavailability of geniciability of Queensland Dioavailability of geniciability of geniciability of geniciability of geniciability of professionals on medication use in breastfeeding: Or Nazrul Islam, Queensland University of Technology Dr Nazrul Islam, Queensland University of Technology Dr Nazrul Islam, Queensland University of Technology Dr Nazrul Islam, Queensland University of Queensland University of Technology Dr Nazrul Islam, Queensland Drevalence of potentially inappropriate medication use in breastfeeding: Or prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic receptor work and cardiac-selective targeting of histone elacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University University of Sydney Dr Karen Gregory, Monash University University of Sydney Dr Rebecca Roubin, The University of Sydney	14:30 – 14:45	Inhibition of the transient			· •
improves cardiac function in an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University of Auckland, New Zealand 14:45 – 15:00 Functional regulation of bitter taste receptors by beta2-adrenergic and MZ muscarinic acetylcholine receptors Mr. Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in mouse model of type 1 diabetes PDr Miles De Blasio, Baker Heart & Diabetes institute Definition of apoptosis in triple negative breast cancer cells by selenium derivatives activity of Technology Monitoring NanoBRET ligand binding to endogenous adenosine AZB receptors Dr Miles De Blasio, Baker Heart & Diabetes institute Definition of Apoptosis in triple negative breast cancer cells by selenium derivatives activity of two national medication use in breastfeeding: Comparative call analysis of two national medications use in breastfeeding: Omitoring NanoBRET ligand binding to endogenous adenosine AZB receptors Dr Miles De Blasio, Baker Heart & Diabetes institute Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dual action calcium sensing receptor modulator, calhew231, unmasks novel mode-switching mechanism University Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University of Sydney Dr Willash Shin Ng, University Dr Rebecca Roubin, The University of Sydney		receptor potential melastatin	conjugated N-trimethyl	for patients with a history of	in glioblastoma therapy
an ex vivo model of ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University Dr Tamara Paravicini, RMIT University of Auckland, New Zealand 14:45 – 15:00 Functional regulation of bitter taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of typ 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Male Cardiomyopathu in diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Mr Andr		7 (TRPM7) channel-kinase	chitosan enhance the oral	atrial fibrillation: An analysis	Assoc Prof Lenka Munoz, The
ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University 14:45 – 15:00 14:45 – 15:00 Functional regulation of bitter taste receptors by beta2- adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University University Dual action calcium sensing receptor modulator, callex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University Assoc Prof Jingyuan Wen, University of Auckland, New Zealand Questions from Australian public and health norestiteding: Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with professionals on medication use in breastfeeding: Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Otago, New Zealand Induction of apoptosis in triple negative breast cancer cells by selenium delevatives Mr Salckmil Puthoor Jogy, University of Otago, New Zealand Induction of apoptosis in triple negative breast cancer cells by selenium delevatives Mr Salckmil Puthoor Jogy, University of Otago, New Zealand Induction of Pevelousens Ms Jeffry Adiavidja, Induction of Induction of Induction		improves cardiac function in	bioavailability of gemcitabine	using MedicineInsight data	University of Sydney
ischaemia/reperfusion injury Dr Tamara Paravicini, RMIT University of Auckland, New Zealand 14:45 – 15:00 Functional regulation of bitter taste receptors by beta2- adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Milso De Blasio, Baker Heart & Diabetes institute Dr Milso De Blasio, Baker Heart & Diabetes institute Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University University Dual action calcium sensing receptor modulator, callex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University University Of South Australia Dr Rebecca Roubin, The University of Sydney MedicineWise Questions from Australian public and health professionals on medication use in breastfeeding: Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with profestate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Ms Huah Shin Ng, University of South Australia Dr Rebecca Roubin, The University of Sydney		an ex vivo model of	by targeting goblet cells	Dr Daniel Taylor, NPS	
Dr Tamara Paravicini, RMIT University of Auckland, New Zealand Functional regulation of bitter taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University of South Australia University of South Australia University of Sydney Description Australian public and health professionals on medication use in breastfeeding: Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Queensland University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Dual action calcium sensing receptor modulator, callex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Dr Karen Gregory, Monash University Dr Karen Gregory, Monash University of Sydney Dr Karen Gregory, Monash University Dr Karen Gregory, Monash University of Sydney Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney		ischaemia/reperfusion injury		MedicineWise	
University Zealand 14:45 - 15:00 Functional regulation of bitter taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland University of Technology Dr Nazrul Islam, Queensland University of Queensland University of Queensland Dr Treasure McGuire, The University of Queensland Dr Treasure McGuire, The University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney University		Dr Tamara Paravicini. RMIT			
14:45 – 15:00 Functional regulation of bitter taste receptors by beta2-adrenergic and M2 muscarinic activity Mr Jilai Zhao, The University of Queensland Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Nicotine-loaded chitosan nanoparticulate dry powder inhaler formulation for its activity professionals on medication use in breastfeeding: Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Queensland Dr Prevalence of potentially inappropriate medication use in breastfeeding: Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Queensland Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Alles De Blasio, Baker Heart & Diabetes institute Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Rozero Fregory, Monash University of Sydney Dr Karen Gregory, Monash University of Sydney Dr Karen Gregory, Monash University of South Australian Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney		· ·			
taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University I taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors inhaler formulation for its activity Dr Nazirul Islam, Queensland University of Technology Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinis Mr Jeffry Adiwidjaja, The University of Sydney Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-sewitching mechanism Dr Karen Gregory, Monash University Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of South Australia	14:45 – 15:00	•		Questions from Australian	Induction of apoptosis in triple
adrenergic and M2 muscarinic acetylcholine receptors Mr Jilai Zhao, The University of Queensland 15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute 15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University inhaler formulation for its activity Dr Nazrul Islam, Queensland University of Cenhology Ms Huah Shin Ng, University of Otago, New Zealand The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney Triterpenoid micellar or comorbidities in men with prostate cancer treated with and receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University Ms Huah Shin Ng, University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of		_	nanoparticulate dry powder	•	
acetylcholine receptors Mr Jilai Zhao, The University of Queensland University of Technology Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Miles De Willis, Monash University Dr Miles De Blasio, Baker Heart & Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Willis De Willis, Monash University Dr Miles De Blasio, Baker Heart & Systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with and of glioblastoma: Potential inhibition of the PI3K/Akt signalling Dr Karen Gregory, Monash University Dr Willis De Blasio, Baker Heart & Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University of Sydney Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney				•	_
Mr Jilai Zhao, The University of Queensland University of Technology Dr Nazrul Islam, Queensland University of Technology Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive imapirment: A systematic review Mr Mitchell Redston, The University of Sydney Dr Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Dr Karen Gregory, Monash University Dr Karen Gregory, Monash University Dr Razzul Islam, Queensland Comparative call analysis of two national medicines call centres Dr Treasure McGuire, The University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive imaparment: A systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Ms Huah Shin Ng, University of Sydney Dr Rebecca Roubin, The University of Sydney University of Otago, New Zealand University of Otago, New Zealand The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the PI3K/Akt signalling Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of South Australian		_		•	
Queensland University of Technology two national medicines call centres Dr Treasure McGuire, The University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney 15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University University University of Technology two national medicines call centres Dr Treasure McGuire, The University of Queensland The effect of curcumin on in vitro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney Dr Alizabeth Johnstone, Harry Perkins Institute of Medical Research Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Ms Huah Shin Ng, University of Sydney Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the PI3K/Akt signalling Dr Rebecca Roubin, The University of Sydney Ws Huah Shin Ng, University of Sydney			1	_	0 7.
15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Dr Karen Gregory, Monash University Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes and predicted in vitro metabolism and predicted in vivo exposure of imatinib without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Mr Andstralian population-based cohort study Mr Huah Shin Ng, University of Sydney Defining the progression of diabetic cardiomyopathu witro metabolism and predicted in vivo exposure of imatinib witro metabolism and predicted in vivo exposure of imatinib Mr Jeffry Adiwidjaja, The University of Sydney Dr Jeffry Adiwidjaja, The University of Sydney Dr Jeffry Adiwidjaja, The University of Sydney Dr Villes De Blasio, Baker Heart & with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Dr Villes De Blasio, Baker Heart & with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the Pl3K/Akt signalling Dr Rebecca Roubin, The University of Sydney					
15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Blizabeth Johnstone, Harry Perkins Institute of Medical Research Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Dr Treasure McGuire, The University of Queensland Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Mr Shuah Shin Ng, University of Sydney Dr Eirabeth Johnstone, Harry Perkins Institute of Medical Research Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University of South Australia Dr Karen Gregory, Monash University of South Australia Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney		Queensiand	University of Technology		Zealand
15:00 – 15:15 Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University Monitoring NanoBRET ligand binding to endogenous adenosine A2B receptors Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Mr Andrew Willis, Monash University of Sydney Mr Huah Shin Ng, University of Sydney Development of comorbidities in men with androgen deprivation therapy: An Australian population-based cohort study Mr Huah Shin Ng, University of Sydney Dr Rebecca Roubin, The University of Sydney					
Defining the progression of diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Defining the progression of diabetes cardiomyopathu in a mouse model of type 1 diabetes cardiomyopathy in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Mr Andrew Willis, Monash University of Sydney Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University of South Australia Dr Rebecca Roubin, The University of Sydney Dr Rebecca Roubin, The University of Sydney					
diabetic cardiomyopathu in a mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University binding to endogenous adenosine A2B receptors Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Dr Miles De Blasio, Baker Heart & Diabetes institute Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with and without cognitive impairment: A systematic review Mr Mitchell Redston, The University of Sydney Development of comorbidities in men with prostate cancer treated with and without cognitive impairment: A systematic review Mr Aleffry Adiwidjaja, The University of Sydney Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the PI3K/Akt signalling Dr Rebecca Roubin, The University of Sydney Ms Huah Shin Ng, University of Sydney	45.00 45.5	56.4			- 6 . 6
mouse model of type 1 diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dr Males De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Matchell Redston, The University of Sydney Mr Mitchell Redston, The University of Sydney Mr Mitchell Redston, The University of Sydney Mr Mitchell Redston, The University of Sydney Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the PI3K/Akt signalling Dr Rebecca Roubin, The University of Sydney Mr Huah Shin Ng, University of South Australia	15:00 – 15:15			1	
diabetes Dr Miles De Blasio, Baker Heart & Diabetes institute Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism University Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism University Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism University Dr Karen Gregory, Monash University Dr Karen Gregory, Monash University Dr Rebecca Roubin, The University of Sydney Mr Jeffry Adiwidjaja, The University of Sydney Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the PI3K/Akt signalling Dr Rebecca Roubin, The University of Sydney		• •		1	•
Dr Miles De Blasio, Baker Heart & Diabetes institute Besearch Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Perkins Institute of Medical Research Mr Mitchell Redston, The University of Sydney Perkins Institute of Medical Research Mr Mitchell Redston, The University of globlastoma: Potential inhibition of the PI3K/Akt signalling Dr Rebecca Roubin, The University of Sydney Ms Huah Shin Ng, University of Sydney		mouse model of type 1	adenosine A2B receptors	•	•
8. Diabetes institute Research		diabetes	Dr Elizabeth Johnstone, Harry	without cognitive	Mr Jeffry Adiwidjaja, The
15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Mr Andrew Willis, Monash University of Sydney Mr Andrew Willis, Monash University of Sydney Mr Andrew Willis, Monash University of Sydney Mr Andrew Willia inhibition of th		Dr Miles De Blasio, Baker Heart	Perkins Institute of Medical	impairment: A systematic	University of Sydney
15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Ms Huah Shin Ng, University of Sydney University of Sydney		& Diabetes institute	Research	review	
15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Ms Huah Shin Ng, University of Sydney Ms Huah Shin Ng, University of Sydney				Mr Mitchell Redston, The	
15:15 – 15:30 Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study Ms Huah Shin Ng, University of Sydney Ms Huah Shin Ng, University of Sydney				University of Sydney	
targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor modulator, calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University receptor mediate and cancer treated with androgen deprivation therapy: An Australian population-based cohort study University of Sydney receptor mediate and cancer treated with androgen deprivation therapy: An Australian population-based cohort study University of Sydney	15:15 – 15:30	Systemic and cardiac-selective	Dual action calcium sensing	· · · · ·	Triterpenoid micellar
deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy Mr Andrew Willis, Monash University Calhex231, unmasks novel mode-switching mechanism Dr Karen Gregory, Monash University Dr Rebecca Roubin, The University of Sydney	2.22	1 -	_	·	I
diabetic cardiomyopathy Mr Andrew Willis, Monash University mode-switching mechanism Dr Karen Gregory, Monash University mode-switching mechanism Dr Karen Gregory, Monash University mode-switching mechanism Dr Karen Gregory, Monash University population-based cohort study Ms Huah Shin Ng, University of South Australia inhibition of the PI3K/Akt signalling Dr Rebecca Roubin, The University of Sydney					=
Mr Andrew Willis, Monash University Dr Karen Gregory, Monash University Dr Rebecca Roubin, The University of Sydney Ms Huah Shin Ng, University of South Australia			•	•	_
University University population-based cohort study University of Sydney Ms Huah Shin Ng, University of South Australia Dr Rebecca Roubin, The University of Sydney			_		
study Ms Huah Shin Ng, University of South Australia University of Sydney		1		• •	, ,
Ms Huah Shin Ng, University of South Australia		University	University	1	
of South Australia				•	University of Sydney
15:30 – 15:55 Afternoon tea with exhibitors				of South Australia	
	15:30 – 15:55	Afternoon tea with exhibitors			

16:00 – 18:00	Oral presentations 5: Pharmacy Practice	Oral presentations 6: Drug Disposition and Response/Pharmaceutical Science	Oral presentations 7: Urogenital and Gastrointestinal	Oral presentations 8: Neuro- and Behavioural Pharmacology
16:00 – 16:15	Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross- sectional study Mr Mulugeta Angamo, University of Tasmania	Troches or orally dissolving tablets for delivery of pilocarpine in treatment of xerostomia (dry mouth)? Mrs Rose Estafanos, The University of Queensland	Pulsed magnetic stimulation for persistent post- prostatectomy stress urinary incontinence: A pilot study Dr Renly Lim, University of South Australia	Morphine dosing affects development of antinociceptive tolerance and motor behaviour Mr Alok Kumar Paul, University of Tasmania
16:15 – 16:30	Investigating the impact of universal healthcare coverage on the practice of Indonesian community pharmacy: A qualitative study Mr Andi Hermansyah, The University of Sydney	Lipophilic salts of small molecule kinase inhibitors for increased oral bioavailability using lipid formulations Dr Hywel Williams, Capsugel	Pharmacological effects of a jungle ginger on rat prostatic smooth muscle Ms Nguok Ngie Eunice Su, Monash University	Increased osmotic pressure promotes glioblastoma invasiveness Miss Wenjun Pu, The University of Queensland
16:30 – 16:45	Home Medicines Reviews - exploring accredited pharmacists' work processes Ms Marea Patounas, Queensland University of Technology	Triglyceride-mimetic prodrugs of testosterone significantly enhance lymphatic transport and oral bioavailability Dr Tim Quach, Monash University	Post-hospital changes in medication regimen complexity and potentially inappropriate medication use in older adults with chronic kidney disease Mr Wubshet Tesfaye, University of Tasmania	Discovering methyllycaconitine analogues specific for α4 β2 over α7 nAChR subtypes Mrs Taima Qudah, The University of Sydney
16:45 – 17:00	Adoption of the Ohio Emergency Department opioid prescribing guidelines Dr Jonathan Penm, The University of Sydney	Characterising and predicting the in vivo kinetics of therapeutic mesenchymal stem cells and their secretome Dr Haolu Wang, The University of Queensland	Effect of Rho-kinase inhibitors on contractility of porcine corpus cavernosum Miss Amelia Jack, Bond University	Inhibition of α5β1 with the clinically validated small peptide ATN-161 is neuroprotective and functionally restorative in experimental stroke Ms Danielle Edwards, University of Kentucky, USA
17:00 – 17:15	Pharmacy in the community: The potential of role extension Dr Caroline Morris, University of Otago, New Zealand	Permeation of quercetin through the human epidermis Dr Azadeh Alinaghi, University of South Australia	The effects of aging on polarization in collagen sandwich-cultured hepatocytes Miss Sun Woo Kang, Anzac Research Institute	Morphine regulates cellular migration and invasion by modifying the circulating proteolytic profile in mice Miss Nan Xie, The University of Queensland
17:15 – 17:30	Just rubbish? Examining the concerns and attitudes of pharmacists to pharmaceuticals entering the environment. Mrs Judith Singleton, Queensland University of Technology	Evaluation of optimised piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa (Pa) for patients with altered pharmacokinetics via the hollow fibre infection model and mechanism-based modelling Mr Rajbharan Yadav, Monash University	Human 5-HT3AC receptors are subtly different to 5-HT3A receptors Prof Helen Irving, La Trobe University	Stress induced analgesia is reduced in neuropathic pain states Mr Nicholas Atwal, The University of Sydney
17:30 – 17:45	Adherence to lipid lowering medications for secondary prevention of stroke Mrs Judith Coombes, The University of Queensland; Princess Alexandra Hospital	CMF-019, the first G protein biased small molecule apelin agonist, is a vasodilator and positive inotrope in vivo Mr Cai Read, University of Cambridge, UK	Characterization of Nav channels in colon-innervating dorsal root ganglion neurons in mice Ms Andelain Erickson, The University of Adelaide	Phytocannabinoid actions in an animal model of neuropathic pain Miss Jessica Falon, The University of Sydney
17:45 – 18:00	Cost-effectiveness of pharmacist management of hypertension Prof Carlo Marra, University of Otago, New Zealand	Polymer precipitation inhibitors can maintain drug supersaturation and increase in vivo absorption from lipid- based formulations Ms Estelle Suys, Monash University	Histamine receptor (Hrh) subtypes mediate bladder afferent sensitivity in mice Ms Ashlee Caldwell, The University of Adelaide	Nesfatin-1 suppresses feeding and induces emesis in Suncus murinus (House Musk Shrew) Dr Sze Wa Chan, Caritas Institute of Higher Education, Hong Kong
19:30 -	AAPS student dinner The Plough Inn, 29 Stanley St, South Brisbane			

Thursday 7 December 2017

08:00 – 17:00	Registration desk open					
08:30 - 09:30	British Pharmacological Society keynote address					
	Innovations in clinical pharmaco	o logy education Versity Medicine Malaysia, Malaysi	a			
09:30 - 10:25	Morning tea with exhibitors	versity ivieutine ividiaysia, ividiaysi	a			
	Poster presentations: Drug Disp		ation/respiratory, Neuro- and Be			
10:30 – 12:30	Symposium 5: Why is	Symposium 6: New strategies	Gastrointestinal, Pharmacy Pract Symposium 7: Novel targets	Symposium 8: Improving		
10.30 12.30	polypharmacy increasing in	to treat chronic inflammatory	for the treatment of pain	Biomolecule behaviour		
	aged care facilities and what	diseases				
	can we do about it?					
			Supported by			
			THE UNIVERSITY OF QUEENSLAND OF STRACES Institute for Molecular Bioscience			
	Chair: Ms Natali Jokanovic	Chairs: Assoc Prof Ross Vlahos and Prof Emilio Badoer	Chairs: Prof Richard Lewis and Assoc Prof Irina Vetter	Chair: Prof Rod Minchin		
10:30 - 11:00	Increasing polypharmacy in	Adipokines, cardiovascular	Decoding spinal cord circuits	CESTEM-1 clinical trials: using		
	aged care facilities: Trends,	function and brain	to find novel targets for chronic pain	dynamin inhibitors to reverse		
	problems and solutions Ms Natali Jokanovic, Monash	inflammation Prof Emilio Badoer, RMIT	Dr Wendy Imlach, Monash	resistance to monoclonal antibody therapy		
	University	University	University	Dr Fiona Simpson, The		
	,	•	,	University of Queensland		
11:00 – 11:30	How is Canada addressing the	Mineralocorticoid and	NaV1.7 as a pain target	i-bodies against the		
	increasing burden of	estrogen receptors: Novel	Dr Sulayman Dib-Hajj, Yale	chemokine receptor CXCR4		
	polypharmacy? Dr Justin Turner, University of	therapeutic targets in cardiovascular disease and	University, USA	with novel pharmacology Dr Michael Foley, La Trobe		
	Montreal, Canada	stroke?		University		
	,	Prof Chris Sobey, Latrobe		,		
		University				
11:30 – 12:00	Integrating prescribing and	Binary GABA-A receptors as	GPCRs and ion channels: The	Antibody-polymer-drug		
	dispensing data across primary care, hospitals and	targets for motor recovery after stroke	cause of and solution to chronic visceral pain?	conjugates for biomedical applications		
	aged care: The MedView	Prof Mary Collins, The	Assoc Prof Stuart Brierley,	Dr Charlotte Williams, CSIRO		
	Project	University of Sydney	Flinders University; SAHMRI			
	Mr David Freemantle, Fred IT					
12:00 – 12:30	Group Application of a structured	Torracting evident denondent	Machanasansans in nain	Downsining disultido viela		
12:00 – 12:30	approach to simplify	Targeting oxidant-dependent pathways to treat cognitive	Mechanosensors in pain Dr Kate Poole, University of	Downsizing disulfide-rich bioactive peptides		
	medication regimens in	dysfunction in chronic	New South Wales	Dr Richard Clark, The University		
	residential aged care	obstructive pulmonary		of Queensland		
	Dr Janet Sluggett, Monash	disease				
	University	Assoc Prof Ross Vlahos, RMIT				
		University				
12:30 – 13:25	Lunch with exhibitors					
		Poster presentations: Drug Disposition and Response, Inflammation/respiratory, Neuro- and Behavioural Pharmacology,				
			Bastrointestinal, Pharmacy Pract			
13:30 – 15:30	Oral presentations 9: Garth	Oral presentations 10:	Oral presentations 11:	Oral presentations 12:		
13:30 – 13:45	McQueen Student Oral prize Gene delivery targeting	Respiratory/Toxicology Vale Domenico (Dom) Spina	Pharmacy Practice Identifying clinical pharmacist	Clinical Pharmacology Microdosed cocktail of		
_0.00 10.70	cardiac O-GlcNAc modification	Emeritus Prof Roy Goldie,	patient prioritisation criteria	apixaban, edoxaban and		
	limits diabetic	Flinders University	Mrs Nazanin Falconer, The	rivaroxaban can predict drug		
	cardiomyopathy		University of Queensland	interaction with therapeutic		
	Mr Darnel Prakoso, The Baker			doses		
	Heart and Diabetes, University of Melbourne			Prof Gerd Mikus, University Hospital Heidelberg, Germany		
13:45 – 14:00	The safety of metformin in	IRAK3 modulates NFкВ	Evaluation of a quantitative	The influence of ABCG2		
25.15 14.00	haemodiafiltration	through its guanylate cyclase	approach for analysis of semi-	genotype on allopurinol dose		
	Miss Felicity Smith, University	activity	structured pharmacy	predictions		
	of New South Wales; St	Ms Lubna Freihat, Monash	consumer interviews	Dr Daniel Wright, University of		
	Vincent's Hospital	University	Mr Ardalan Mirzaei, The	Otago, New Zealand		
			University of Sydney	<u> </u>		

14:00 – 14:15	Neuronal calcium sensor-1 (NCS-1) in the regulation of	Intranasal delivery of the TLR7 agonist, imiquimod, protects	Response of community pharmacy staff to a request	Late onset rise of 6-MMP metabolites in inflammatory	
	calcium homeostasis and cell		1	,	
		against influenza A virus-	for an antibiotic product	bowel disease patients on	
	death in MDA-MB-231 basal	induced morbidity in mice	without a valid prescription: A	azathioprine or	
	breast cancer cells	Mr Jonathan Erlich, RMIT	simulated client study in Sri	mercaptopurine	
	Miss Alice Bong, The University	University	Lanka	Prof Murray Barclay,	
	of Queensland		Mr Shukry Zawahir, The	Christchurch Hospital, New	
4445 4430			University of Sydney	Zealand	
14:15 – 14:30	The relationship between	A novel endosomal NOX2	Development of a website	Minimising the functional	
	busulphan AUC and the	oxidase inhibitor protects	to demystify polypharmacy	burden of medications in older	
	incidence of sinusoidal	against high pathogenicity	through clinician input	inpatients: Implementation of	
	obstruction syndrome in	influenza A virus-induced	Nashwa Masnoon,	the Drug Burden Index	
	haematopoietic stem cell	disease	University of South	Ms Rayan Nahas, Royal North	
	transplants	Ms Eunice To, RMIT University	Australia	Shore Hospital	
	Mr Parth Upadhyay, The				
14.20 14.45	University of Sydney	Landination of mahammin in	Davels atmosfis and distance area in	A stimulation study to access	
14:30 – 14:45	An investigation of the	Localisation of polymyxin in	Psychotropic medicines use in	A stimulation study to assess	
	vascular effects of Sailuotong, a standardised Chinese herbal	human alveolar epithelial cells Mr Maizbha Uddin Ahmed,	Residents and Culture: Influencing Clinical Excellence	the possible contribution of	
		,		measurement error in	
	formula, for vascular dementia	Monash University	(PRACTICE) tool: A development and content	quetiapine depression trials Ms Jia Ning Careen Tan, The	
			validation study	University of Queensland	
	Miss Seungyeon Yeon, Western		Miss Mouna Sawan, The	Offiversity of Queeristand	
	Sydney University; The Science				
14:45 – 15:00	of Integrative Medicine (NICM)		University of Sydney	A manufaccatus casas label	
14:45 – 15:00	Understanding the		"Good prescribing is a bit like	A multicentre open-label pharmacokinetic-	
	physiological role of		good driving; everybody	1 •	
	endogenous allosteric modulators in the muscarinic		thinks they're a good driver."	pharmacodynamic study of	
			An exploratory study on the	febuxostat in patients with	
	acetylcholine receptors		barriers and facilitators to	chronic gout	
	Ms Ee Von Moo, Monash		using quality prescribing	Mr Bishoy Kamel, University of	
	University		indicators (QPIs) in general practice	New South Wales; St Vincent's Hospital	
			•	ПОЅРІТАІ	
			Dr Li Shean Toh, University of Tasmania		
15:00 – 15:15	Behavioural, pharmacologic	Getting under the skin – why	Contextualised medication	The safety and	
15.00 15.15	and histologic characterisation	receptor fluid choice is crucial	information is critical to	pharmacokinetics of metformin	
	of a rat model of mechanical	in in vitro skin permeation	treatment uptake and	in heart failure	
	low back pain	tests	adherence among people	Mrs Gina Chowdhury, University	
	Mr Thomas Park, The	Dr Ana Macedo, University of	living with HIV	of New South Wales; St	
	University of Queensland	South Australia	Dr Amary Mey, Griffith	Vincent's Hospital	
	C. Treforty of Queensiana		University	scrie s riospital	
15:15 – 15:30	The Medication Regimen	Can an educational	A study on usual Residential	Vignettes from hospital-level	
	Simplification Guide for	intervention lead to a	Medication Management	electronic prescribing data	
	Residential Aged CarE (MRS	sustained reduction in gastric	Review (RMMR) practice	Dr Paul Chin, Canterbury District	
	GRACE): A novel tool to	lavage for poisoning	Mrs Leila Shafiee Hanjani, The	Health Board, New Zealand	
	optimise medication regimens	admissions?	University of Queensland	22.3, 12.1 20.010	
	for residents of aged care	Dr Jacques Raubenheimer, The			
	facilities.	University of Sydney			
	Ms Esa Chen, Monash University				
15:30 – 15:55	Afternoon tea with exhibitors				
16:00 – 17:00	ASCEPT Rand Medal Lecture				
	Prof Nicholas Buckley, Sydney Medical School, The University of Sydney				
17:00 – 18:00	ASCEPT AGM				
19:00 – 23:00	Meeting dinner				
	Boulevard Room, Brisbane Convention and Exhibition Centre				

Friday 8 December 2017

07:30 – 15:45	Registration desk open				
08:30 - 09:30	APSA Medal Oration				
	Prof Chris Porter, Monash Inst	itute of Pharmaceutical Sciences	(MIPS), Monash University		
09:30 - 10:25	Morning tea with exhibitors and poster presentations				
10:30 - 12:30	Symposium 9: The ethics of	Symposium 10: The blood-	Symposium 11: Certara New	Symposium 12: APSA Early	
	selling or recommending	brain barrier: A regulator of	Investigator Award	Career Researchers finalists	
	complementary medicines	CNS drug access and disease			
	Chancarad by	progression Sponsored by	Sponsored by		
	Sponsored by	Sponsored by			
	Cittin	GENES EARCH :	CERTARA		
	UNIVERSITY	e * F R E E Z E R	•	I	
	QUALITY USE OF MEDICINES				
	NETWORK QUM				
	Chair: Dr Jasmina Fejzić	Chair: Dr Joe Nicolazzo	Chair: Carl Kirkpatrick		
10.20 11.00	,		·		
10:30 – 11:00	Complementary medicines, health professional	Regulating transporters at the blood-brain barrier to treat	The use of oral anticoagulants in people	How to reliably measure customers' perceptions of	
	responsibilities and trust	glioblastoma multiforme	with dementia	service quality in community	
	Prof Eleanor Milligan, Griffith	Prof William Elmquist,	Jenni Ilomaki, Monash	pharmacy	
	University	University of Minnesota, USA	University	Dr Stephen Carter, The	
11:00 – 11:30	What are the netential horses	The role of the neurovascular	Strategies for presiden use	University of Sydney The safety of transdermal	
11:00-11:30	What are the potential harms of complementary medicines?	unit in neurodegenerative	Strategies for precision use of targeted anti-cancer	fentanyl initiation in Australian	
	Dr Geraldine Moses, Mater	diseases	medicines	clinical practice	
	Hospital; The University of	Prof Cheryl Wellington	Andrew Rowland, Flinders	Dr Natasa Gisev, University of	
	Queensland	University of British Columbia,	University	New South Wales	
11:30 – 12:00	Selling complementary	Canada HIV infection and Alzheimer's	Big data: Driving Innovation		
11.50 12.00	medicines and the new Code	disease: The integral role of	for Geriatric	Personalized Microneedle Eye	
	of Ethics for Pharmacists	the blood-brain barrier	Pharmacoepidemiology and	Patches by 3D Printing to Treat	
	Dr Adam La Caze, The	Prof Michal Toborek,	Pharmacovigilance	Peri-orbital Wrinkles with a	
	University of Queensland	University of Miami, USA	Research Prasad Nishtala, University of	Small Peptide Dr Lifeng Kang, The University	
			Otago	of Sydney	
12:00 – 12:30	Regulating complementary	The cerebral vascular	Developing the next	The provision of enhanced	
	medicines and pharmacy	basement membrane: A	generation of analgesics	and extended services in	
	practice Assoc Prof Laetitia Hattingh,	target for Alzheimer's disease and stroke	Jennifer Deuis, The University of Queensland	Western Australian Community Pharmacies	
	Griffith University	Prof Gregory Bix, University of	or Queerisiana	Dr Petra Czarniak, Curtin	
	,	Kentucky, USA		University	
12:30 – 13:25		PT student poster finalists present			
13:30 – 15:00	Oral presentations 13:	Oral presentations 14:	earch and Practice, NPS Medicir Oral presentations 15:	Oral presentations 16:	
13.30 13.00	Drug Discovery /	Clinical trainees	Pharmacogenomics	Education	
	Pharmaceutical Science				
13:30 – 13:45	Reversal of age related	A randomised controlled trial	No significant effect of CYP3A,	Best Possible Medication	
	pseudocapillarization utilizing	of patient information leaflets	ABCB1, POR and NR1I2	History Gamification –	
	vascular endothelial growth factor related, nitric oxide	as a medication counselling tool	polymorphisms on acute rejection and nephrotoxicity in	development and pilot study Dr Paulina Stehlik, Bond	
	dependent drug treatments	Dr Richard McNeill, Canterbury	the first 3 months post kidney	University	
	on in vitro liver sinusoidal	District Health Board, New	transplantation in patients		
	endothelial cells	Zealand	receiving tacrolimus		
	Dr Nicholas Hunt, Anzac Research Institute, The		Ms Rong Hu, The University of Adelaide		
	University of Sydney				
13:45 – 14:00	Cell-specific and biased	"Therapy induced" Takotsubo	HLA-B status leading to	Engaging students in learning	
	signalling of a peptide mimetic	Cardiomyopathy: Does it	potential severe adverse drug	outcomes and career	
	and small molecule at the	matter?	reactions in Aboriginal	relevance through a multi-	
	relaxin receptor RXFP1 Dr Martina Kocan, Florey	Dr Gao Jing Ong, Queen Elizabeth Hospital	Australians Prof Andrew Somogyi,	dimensional, interactive map – MyCourseMap	
	Institute of Neuroscience and		University of Adelaide	Assoc Prof Lisa Tee, Curtin	
	Mental Health			University	

14:00 – 14:15	Investigation of the insulin mimetic effect of Teucrium polium in vitro Dr Rima Caccetta, Curtin University	A physiological based pharmacokinetic model to guide dosing of ivacaftor in the presence of pharmacoenhancers. Dr Angela Rowland, Flinders Medical Centre	Potential simple and multifactorial drug and gene interactions of tricyclic antidepressants in older Australians Mr Mohitosh Biswas, The University of Newcastle	"Visual thinking strategies" in early pharmacy undergraduate education can support the development of professional communication and cultural competencies Dr Trudi Aspden, University of Auckland, New Zealand
14:15 – 14:30	Measuring ligand-binding in endosomes: A signalling platform for pain transmission Dr Nicholas Veldhuis, Monash University	Evaluation of the role and impact of brain computed tomography scans in the assessment of clinically diagnosed overdose cases and an attempt to formulate a procedural framework. Dr Emma Tay, St Vincent's Hospital	Signalling modification by Single Nucleotide Polymorphisms in the third intracellular loop of the mu-opioid receptor Dr Marina Junqueira Santiago, Macquarie University	Experiences developing a pharmacology online careers portal: Evaluating impact on student career awareness Dr Barbara Kemp-Harper, Monash University
14:30 – 14:45	Mutations in the NPxxY motif stabilise different conformational states of the α1B- and β2-adrenoceptors Dr Lotten Ragnarsson, The University of Queensland	Real-time review of electronic prescribing of restricted antimicrobials - a pilot of a new antimicrobial stewardship initiative for Christchurch Hospital Dr Niall Hamilton, Canterbury District Health Board, New Zealand	ABCB1 pharmacogenetics in Papua New Guinea HIV/AIDS patients and association with efavirenz CNS/Psychiatric adverse effects Miss Helena Van Schalkwyk, University of Adelaide	Exploring the use of a novel computer-based interactive pharmacy simulation program in university and professional pharmacy practice education Dr Kenneth Lee, University of Tasmania
14:45 – 15:00	Drug delivery to the intestinal lymphatics enhances the immunosuppressant effects of mycophenolic acid in mice Mrs Ruby Panakkal Kochappan, Monash University	Thyroid immune-related adverse events following PD-1 inhibitors for cancer: Characteristics and associations Dr Frida Djukiadmodjo, Austin Health	Interleukin genetics and not COMT or OPRM1 may affect risk of persistent pain following total knee arthroplasty Dr Daniel Barratt, University of Adelaide	The journey of a prescription: An interprofessional education simulation of the patient and prescription flow through prescriber and dispenser Dr James Green, University of Otago, New Zealand
15:00 – 15:15	Comfort break			
15:15 – 15:45	Awards and meeting close			